These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 9916724)

  • 21. Reduced diversity of CTLs specific for multiple minor histocompatibility antigens relative to allograft rejection in vivo.
    Nevala WK; Paul C; Wettstein PJ
    J Immunol; 1997 Feb; 158(3):1102-7. PubMed ID: 9013948
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Escape mechanisms of melanoma from immune system by soluble melanoma antigen.
    Takahashi K; Ono K; Hirabayashi Y; Taniguchi M
    J Immunol; 1988 May; 140(9):3244-8. PubMed ID: 2452202
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination.
    Lee KH; Panelli MC; Kim CJ; Riker AI; Bettinotti MP; Roden MM; Fetsch P; Abati A; Rosenberg SA; Marincola FM
    J Immunol; 1998 Oct; 161(8):4183-94. PubMed ID: 9780192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rejection of a nonimmunogenic melanoma by vaccination with natural melanoma peptides on engineered antigen-presenting cells.
    Bellone M; Iezzi G; Martin-Fontecha A; Rivolta L; Manfredi AA; Protti MP; Freschi M; Dellabona P; Casorati G; Rugarli C
    J Immunol; 1997 Jan; 158(2):783-9. PubMed ID: 8992995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation requirements, lytic mechanism, and development of a novel anti-CD8-resistant CTL population.
    McCarthy SA; Mainwaring MS; Dougall DS; Lamouse-Smith ES
    J Immunol; 1998 Mar; 160(6):2715-24. PubMed ID: 9510171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma.
    Bellone M; Cantarella D; Castiglioni P; Crosti MC; Ronchetti A; Moro M; Garancini MP; Casorati G; Dellabona P
    J Immunol; 2000 Sep; 165(5):2651-6. PubMed ID: 10946294
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses.
    Lu J; Higashimoto Y; Appella E; Celis E
    J Immunol; 2004 Apr; 172(7):4575-82. PubMed ID: 15034075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tracking in vivo migration and distribution of antigen-specific cytotoxic T lymphocytes by 5,6-carboxyfluorescein diacetate succinimidyl ester staining during cancer immunotherapy.
    Xu WL; Li SL; Wen M; Wen JY; Han J; Zhang HZ; Gao F; Cai JH
    Chin Med J (Engl); 2013 Aug; 126(16):3019-25. PubMed ID: 23981604
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of melanoma antigen and its involvement in tumor-escape mechanisms.
    Taniguchi M; Sakatsume M; Harada Y; Nores GA; Hakomori S
    Princess Takamatsu Symp; 1988; 19():247-54. PubMed ID: 2978619
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cutting edge: induction of enhanced CTL-dependent protective immunity in vivo by N-end rule targeting of a model tumor antigen.
    Tobery T; Siliciano RF
    J Immunol; 1999 Jan; 162(2):639-42. PubMed ID: 9916680
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A synthetic peptide derived from the tumor-associated protein mdm2 can stimulate autoreactive, high avidity cytotoxic T lymphocytes that recognize naturally processed protein.
    Dahl AM; Beverley PC; Stauss HJ
    J Immunol; 1996 Jul; 157(1):239-46. PubMed ID: 8683121
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human antitumor CD8+ T cells producing Th1 polycytokines show superior antigen sensitivity and tumor recognition.
    Wilde S; Sommermeyer D; Leisegang M; Frankenberger B; Mosetter B; Uckert W; Schendel DJ
    J Immunol; 2012 Jul; 189(2):598-605. PubMed ID: 22689880
    [TBL] [Abstract][Full Text] [Related]  

  • 33. T cell tolerance based on avidity thresholds rather than complete deletion allows maintenance of maximal repertoire diversity.
    Sandberg JK; Franksson L; Sundbäck J; Michaelsson J; Petersson M; Achour A; Wallin RP; Sherman NE; Bergman T; Jörnvall H; Hunt DF; Kiessling R; Kärre K
    J Immunol; 2000 Jul; 165(1):25-33. PubMed ID: 10861031
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy can reject intracranial tumor cells without damaging the brain despite sharing the target antigen.
    Bridle BW; Li J; Jiang S; Chang R; Lichty BD; Bramson JL; Wan Y
    J Immunol; 2010 Apr; 184(8):4269-75. PubMed ID: 20237288
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel immunotherapeutic approach to melanoma-bearing hosts with protein-transduction domain-containing immunogenic foreign antigens.
    Kanzaki M; Okamoto T; Mitsui H; Shibagaki N; Shimada S
    J Dermatol Sci; 2010 Nov; 60(2):84-94. PubMed ID: 20864317
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CTLA-4 blockade enhances the CTL responses to the p53 self-tumor antigen.
    Hernández J; Ko A; Sherman LA
    J Immunol; 2001 Mar; 166(6):3908-14. PubMed ID: 11238635
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of CD8+ cytotoxic T lymphocyte/tumor cell interactions reflecting recognition of an endogenously expressed murine wild-type p53 determinant.
    Hilburger Ryan M; Abrams SI
    Cancer Immunol Immunother; 2001 Jan; 49(11):603-12. PubMed ID: 11225991
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cross-priming of CTL responses in vivo does not require antigenic peptides in the endoplasmic reticulum of immunizing cells.
    Schoenberger SP; van der Voort EI; Krietemeijer GM; Offringa R; Melief CJ; Toes RE
    J Immunol; 1998 Oct; 161(8):3808-12. PubMed ID: 9780143
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction of antitumor immunity by proteasome-inhibited syngeneic fibroblasts pulsed with a modified TAA peptide.
    El-Shami KM; Tirosh B; Popovic D; Carmon L; Tzehoval E; Vadai E; Feldman M; Eisenbach L
    Int J Cancer; 2000 Jan; 85(2):236-42. PubMed ID: 10629083
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined stimulation of TLR9 and 4.1BB augments Trp2 peptide vaccine-mediated melanoma rejection by increasing Ag-specific CTL activity and infiltration into tumor sites.
    Sin JI; Kim H; Ahn E; Jeon YH; Park WS; Lee SY; Kwon B
    Cancer Lett; 2013 Apr; 330(2):190-9. PubMed ID: 23219755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.